HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Avon’s Dismal Q1 Makes Coty Bid More Appealing – Analysts

This article was originally published in The Rose Sheet

Executive Summary

The first fiscal quarter of 2012 was “unexpectedly weak” for Avon Products, with sales down 2% to $2.6 billion and net income plummeting 82% to $26.5 million, making clear the challenges ahead for the firm and its new CEO. Analysts believe Coty may have a better chance of acquiring the New York-based direct seller in light of the Q1 results.

You may also be interested in...



Analysts Mull Avon’s Future Following Coty’s Dropped Bid

Coty’s withdrawal of $10.7 billion bid for Avon sent shockwaves through investment community and has analysts speculating on whether the direct seller will entertain more offers or pursue its turnaround as stand-alone entity under CEO Sheri McCoy.

Coty Flexes Financial Muscle With Increased Avon Bid, Sets Deadline

Coty ups its offer for Avon, bringing in friends with deep pockets to help finance the deal. The New York-based firm sets a May 14 deadline for Avon to consider its new bid of $24.75 per share.

Can Avon CEO McCoy Rise To “Superhuman” Task?

New CEO Sheri McCoy comes to Avon from Johnson & Johnson with a strong background in consumer products and a “significant turn-around track record,” according to Avon. However, “there is no cape flowing behind her,” notes Morningstar analyst Lauren DeSanto, speculating that Avon’s problems may require superhuman powers.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS018078

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel